Neurofibrillary pathology in Alzheimer disease with Lewy bodies: Two subgroups

Archives of Neurology

Volumn 56, Issue 2, 1999, Pages 203-208

  Gearing, Marla ^a   Lynn, Michael ^b   Mirra, Suzanne S ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; FEMALE; HUMAN; LEWY BODY; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; PATHOGENESIS; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; FEMALE; FRONTAL LOBE; HUMANS; IMMUNOHISTOCHEMISTRY; LEWY BODIES; MALE; MIDDLE AGED; NEUROFIBRILLARY TANGLES; PARIETAL LOBE; TEMPORAL LOBE;

EID: 0032980493     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.2.203     Document Type: Article

References (28)

1. Crystal HA, Dickson DW, Lizardi JE, Davies P, Wolfson LI. Antemortem diagnosis of diffuse Lewy body disease. Neurology. 1990;40:1523-1528.
2. Ditter SM, Mirra SS. Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients. Neurology. 1987;37:754-760.
3. Hansen L, Salmon D, Galasko D. et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology. 1990;40:1-8.
4. Kosaka K. Diffuse Lewy body disease in Japan. J Neurol. 1990;237:197-204.
5. Leverenz J, Sumi SM, Parkinson's disease in patients with Alzheimer's disease. Arch Neurol. 1986;43:662-664.
6. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479-486.
7. Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK. Senile dementia of Lewy body type: a clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci. 1990;85:119-139.
8. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology. 1996;47:1113-1124.
9. Hansen LA, Masliah E, Galasko D, Terry RD. Plaque-only Alzheimer disease is usually the Lewy body variant, and vice versa. J Neuropathol Exp Neurol. 1993;52. 648-654.
10. Hulette C, Mirra S, Wilkinson W, Heyman A, Fillenbaum G, Clark C. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), IX: a prospective cliniconeuropathologic study of Parkinson's features in Alzheimer's disease, Neurology. 1995;45:1991-1995.
11. Lippa CF, Smith TW, Swearer JM. Alzheimer's disease and Lewy body disease: a comparative clinicopathological study. Ann Neurol. 1994;35:81-88.
12. Nagy Z, Esiri MM, Jobst KA, et al. The effects of additional pathology on the cognitive deficit in Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:165-170.
13. Gearing M, Schneider JA, Robbins RS, et al. Regional variation in the distribution of apolipoprotein E and Aß in Alzheimer's disease. J Neuropathol Exp Neurol. 1995;54:833-841.
14. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239-259.
15. Samuel W, Galasko D, Masliah E, Hansen LA. Neocortical Lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. J Neuropathol Exp Neurol. 1996;55:44-52.
16. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol. 1985;42:1097-1105.
17. The National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging. 1997;18(suppl 4):S1-S2.
18. Mega MS, Masterman DL, Benson DF, et al. Dementia with Lewy bodies: reliability of validity of clinical and pathologic criteria. Neurology 1996;47:1403-1409.
19. Hansen LA, Samuel W. Criteria for Alzheimer's disease and the nosology of dementia with Lewy bodies. Neurology. 1997;48:126-132.
20. Mirra SS. The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary. Neurobiol Aging 1997;18(suppl 4):S91-S94.
21. Morris JC, Storandt M, McKeel DW Jr, et al. Cerebral amyloid deposition and diffuse plaques in "normal" aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology. 1996;46:707-719.
22. Eagger SA, Harvey RJ. Clinical heterogeneity: responders to cholinergic therapy. Alzheimer Dis Assoc Disord. 1995;9(suppl 2):37-42.
23. Harrell LE, Jope RS, Falgout J, et al. Biological and neuropsychological characterization of physostigmine responders and nonresponders in Alzheimer's disease. J Am Geriatr Soc. 1990;38:113-122.
24. Levy R, Eagger S, Griffiths M, et al. Lewy bodies and response to tacrine in Alzheimer's disease. Lancet. 1994;343:176.
25. Perry EK, Haroutunian V, Davis KL, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport. 1994;5:747-749.
26. Wilcock GK, Scott MI. Tacrine for senile dementia of Alzheimer's or Lewy body type. Lancet. 1994;344:544.
27. Perry EK, Marshall E, Kerwin J, et al. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem. 1990;55:1454-1456.
28. Samuel W, Alford M, Hofstetter CR, Hansen LA. Dementia with Lewy bodies versus pure Alzheimer disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. J Neuropathol Exp Neurol. 1997;56: 499-508.